Review Article
Metabolism Is Central to Tolerogenic Dendritic Cell Function
Table 1
Dendritic cell therapeutics.
| Condition | Organism | Adjuvant | Metabolic modulator | Immune response | References |
| Psoriasis | Human | 1,25(OH)2D3 | Yes | Increased CD4+CD25+ suppressor T cells | [13] |
| Skin transplant | Mouse | 1,25(OH)2D3 | Yes | Increased CD25+Foxp3+ Tregs | [14] |
| Allograft rejection | Mouse | Dexamethasone | Yes | Increased ratio IL-10/IL-12 | [15] |
| Colitis | Mouse |
1,25(OH)2D3 & dexamethasone | Yes | Lower CD4+CD25− T cell response | [16] |
| Heart graft | Mouse | Rapamycin | Yes | Inhibiting T cell IL-2 & IFN-γ production | [17] |
| Heart graft | Mouse | Rapamycin | Yes | Stimulating CD4+CD25+Foxp3+ Treg | [18] |
| Type-1 diabetes | Human | Antisense oligonucleotides targeting CD40, CD80, and CD86 | No | Stimulating B220+ CD11c− B-cells | [19] |
| Rheumatoid Arthritis | Human | BAY 11-7082 | No | Higher ratio Treg/effector T cells | [20] |
|
|